Search results
Results From The WOW.Com Content Network
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998. Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins.
University of California, San Diego. Lawrence S.B. Goldstein (born February 20, 1956, in Buffalo, New York) is a professor of cellular and molecular medicine at University of California, San Diego and investigator with the Howard Hughes Medical Institute. [1] He receives grant funding from the NIH, the Johns Hopkins ALS Center, the HighQ ...
Shares of the San Francisco-based Cytokinetics surged over 80% to touch a more than a 19-year high of $83.82, on track to add as much as $3.74 bi Cytokinetics heart drug succeeds in closely ...
The Foundation's first therapy concept was to replace EAAT2 protein using gene therapy. In 2004, the Foundation moved to a 16,000-square-foot (1,500 m 2) location in Cambridge, Massachusetts with an in-house lab. ALS TDF constructed a biosafety level 2 lab in 2005, allowing for the expansion of "gene therapy and cell-based treatment pipelines."
In late December, Cytokinetics' shares jumped over 82% after aficamten met the main goal of a keenly awaited late-stage study, putting it on track to compete with a rival treatment from Bristol ...
James A. Spudich ( / ˈspʊdɪtʃ / [1]) is an American scientist and professor. He is the Douglass M. and Nola Leishman Professor of Biochemistry and of Cardiovascular Disease at Stanford University and works on the molecular basis of muscle contraction. He was awarded the Albert Lasker Basic Medical Research Award in 2012 with Michael Sheetz ...
Wallach and his wife, Sandra Abrevaya, have co-founded two organizations focused on ALS. In 2019, they launched I AM ALS, a non-profit seeking to find a cure for ALS through funding and expanding access to research. In 2022 they founded Synapticure, a telemedicine company that provides care to those living with ALS, PLS, and Parkinson's.
Novartis may attempt to pursue a deal for Cytokinetics in the future or a different suitor may acquire the company, the person said. On Monday, Reuters reported that Novartis is in the lead to ...